Table 4.
Summary of best response to treatment (response-evaluable population)
| Total (N = 54) | Arm 1: pevonedistat + docetaxel (n = 19) | Arm 2a (lead-in cohort): pevonedistat + carboplatin (n = 6) | Arm 2: pevonedistat + carboplatin + paclitaxel (n = 23) | Arm 3: pevonedistat + gemcitabine (n = 6) | |
|---|---|---|---|---|---|
| ORR (CR + PR), n (%) | 12 (22) | 3 (16) | 1 (17) | 8 (35) | 0 (0) |
| CR | 2 (4)a | 0 (0) | 0 (0) | 2 (9) | 0 (0) |
| PR | 10 (19)b | 3 (16) | 1 (17) | 6 (26) | 0 (0) |
| SD, n (%) | 29 (54) | 9 (47) | 3 (50) | 12 (52) | 5 (83) |
| PD, n (%) | 13 (24) | 7 (37) | 2 (33) | 3 (13) | 1 (17) |
Abbreviations: CR, complete response; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease
aTumor types: bladder carcinoma (patient received prior platinum therapy) and endometrial cancer (patient received both platinum and taxane as prior therapy)
bTumor types: biphasic hepatocellular carcinoma and cholangiocarcinoma, breast cancer, cholangiocarcinoma, follicular dendritic cell sarcoma, salivary gland carcinoma, squamous cell carcinoma of the head and neck not otherwise specified, squamous cell carcinoma of the oropharynx, squamous non-small cell lung cancer, and parotid gland carcinoma